The successful demonstration of efficacy and tolerability in a non-human primate model meaningfully advances Addex's GABAB PAM program toward clinical development for chronic cough. Traders should monitor for upcoming IND filing or Phase 1 trial initiation, which would be the next value-inflection milestone.
Price Chart
Executive Summary
Addex Therapeutics announced robust anti-tussive activity of its GABAB PAM drug candidate in a non-human primate chronic cough model, demonstrating efficacy comparable to baclofen but with a potentially improved safety and tolerability profile. This preclinical data supports the candidate's potential as a once-daily treatment for chronic cough.
Key Facts
- GABAB PAM candidate significantly reduced citric acid-induced cough frequency in non-human primates.
- Efficacy in the NHP model was similar to baclofen, a drug used off-label for chronic cough.
- Preclinical data show superior antitussive efficacy compared to nalbuphine, codeine, and P2X3 inhibitors in guinea pig models.
- The candidate demonstrated better tolerability and a wider therapeutic margin than baclofen, nalbuphine, and codeine.
- No signs of tolerance were observed after sub-chronic treatment in guinea pigs.
Financial Impact
No direct financial impact reported; this is preclinical data. However, positive results de-risk the program and may enhance future partnership or licensing potential.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- The company remains early-stage with no near-term revenue; funding risk exists for advancing the program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002589 |
| Exhibit: exh_991.htm | 0001171843-26-002589 |
| Document: 0001171843-26-002589-index-headers.html | 0001171843-26-002589 |
| Document: 0001171843-26-002589-index.html | 0001171843-26-002589 |
| Document: 0001171843-26-002589.txt | 0001171843-26-002589 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.18 | awaiting T+60 | — | $2.97 (−6.60%) |
Oct 2, 2026 24d ago | 6-K | $3.07 | awaiting T+60 | — | $2.97 (−3.26%) |
Sep 28, 2026 28d ago | 6-K | $2.81 | awaiting T+60 | — | $2.97 (−5.69%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.97 (−18.63%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.97 (+29.79%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.97 (−49.58%) |
Jun 30, 2026 16w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.97 (+47.89%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.97 (+50.00%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.97 (+56.52%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.97 (−51.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers